Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

  All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:27:28 ON 10 AUG 2005

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:27:48 ON 10 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2005 HIGHEST RN 859282-03-4
DICTIONARY FILE UPDATES: 9 AUG 2005 HIGHEST RN 859282-03-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> E "4-HYDROXYTAMOXIFEN"/CN 25
E1            1     4-HYDROXYSTYRYL PHENYL KETONE POTASSIUM SALT/CN
E2            1     4-HYDROXYTACRINE/CN
E3            1 --> 4-HYDROXYTAMOXIFEN/CN
E4            1     4-HYDROXYTAMOXIFEN ACID/CN
E5            1     4-HYDROXYTECOMANINE/CN
E6            1     4-HYDROXYTESTOSTERONE/CN
E7            1     4-HYDROXYTESTOSTERONE 17-HEMISUCCINATE/CN
```

```
E8            1     4-HYDROXYTESTOSTERONE 17-TERT-BUTYLDIMETHYLSILYL ETHER/CN
E9            1     4-HYDROXYTESTOSTERONE 4-HEMIGLUTARATE/CN
E10           1     4-HYDROXYTESTOSTERONE 4-HEMISUCCINATE/CN
E11           1     4-HYDROXYTETRACHLOROBENZONITRILE/CN
E12           1     4-HYDROXYTETRACHLOROPYRIDINE/CN
E13           1     4-HYDROXYTETRACYCLOXIDE/CN
E14           1     4-HYDROXYTETRADECANE/CN
E15           1     4-HYDROXYTETRAFLUOROBENZOIC ACID/CN
E16           1     4-HYDROXYTETRAFLUOROBENZOIC ACID 1-METHYLHEPTYL ESTER/CN
E17           1     4-HYDROXYTETRAFLUOROBENZOIC ACID OCTYL ESTER/CN
E18           1     4-HYDROXYTETRAFLUOROPYRIDINE/CN
E19           1     4-HYDROXYTETRAFLUOROPYRIDINE POTASSIUM SALT/CN
E20           1     4-HYDROXYTETRAFLUOROPYRIDINE SODIUM SALT/CN
E21           1     4-HYDROXYTETRAHYDRO-2H-PYRAN/CN
E22           1     4-HYDROXYTETRAHYDRO-3-FURANYL NITRITE/CN
E23           1     4-HYDROXYTETRAHYDROFURAN-2,4-DIMETHANOL/CN
E24           1     4-HYDROXYTETRAHYDROFURAN-2-METHANOL/CN
E25           1     4-HYDROXYTETRAHYDROPYRAN/CN

=> S E3
L1            1 4-HYDROXYTAMOXIFEN/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   68047-06-3  REGISTRY
CN   Phenol, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-
     (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Phenol, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-,
     (Z)-
OTHER NAMES:
CN   (Z)-4-Hydroxytamoxifen
CN   4-Hydroxytamoxifen
CN   4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol
CN   Hydroxytamoxifen
CN   ICI 79280
CN   trans-4-Hydroxytamoxifen
CN   trans-Hydroxytamoxifen
FS   STEREOSEARCH
DR   65213-48-1, 72732-26-4, 76276-99-8
MF   C26 H29 N O2
CI   COM
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CAPLUS, CASREACT, CEN, CHEMCATS, CIN, CSCHEM, DDFU,
       DRUGU, EMBASE, IMSDRUGNEWS, IPA, NIOSHTIC, PHAR, PROMT, RTECS*,
       TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Conference; Dissertation; Journal; Patent
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process);
       PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL (Biological
       study); PREP (Preparation); PROC (Process); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
       (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  ANST (Analytical
       study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation);
```

```
       PROC (Process); PRP (Properties); USES (Uses)

Double bond geometry as shown.

/ Structure 1 in file .gra /


**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

            1268 REFERENCES IN FILE CA (1907 TO DATE)
              35 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            1273 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       7.30       7.51

FILE 'MEDLINE' ENTERED AT 16:28:48 ON 10 AUG 2005

 FILE LAST UPDATED: 9 AUG 2005 (20050809/UP).  FILE COVERS 1950 TO DATE.

 On December 19, 2004, the 2005 MeSH terms were loaded.

 The MEDLINE reload for 2005 is now available.  For details enter HELP
 RLOAD at an arrow promt (=>).  See also:

    http://www.nlm.nih.gov/mesh/
    http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

 OLDMEDLINE now back to 1950.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2005 vocabulary.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l1
L2           0 L1

=> s 4-HYDROXYTAMOXIFEN/CN
L3         666 4-HYDROXYTAMOXIFEN/CN  (10 TERMS)
                 ("4-HYDROXYTAMOXIFEN"+XUSE/CN)

=> s breast or mammar?
        197959 BREAST
          3409 BREASTS
        198389 BREAST
                 (BREAST OR BREASTS)
         54038 MAMMAR?
L4      233739 BREAST OR MAMMAR?

=> s density
        243455 DENSITY
         24925 DENSITIES
L5      256821 DENSITY
                 (DENSITY OR DENSITIES)

=> s l5 (S) l4
L6        1500 L5 (S) L4
```

```
=> s l6 and l3
L7            2 L6 AND L3

=> d ibib 1-2

L7   ANSWER 1 OF 2     MEDLINE on STN
ACCESSION NUMBER:    84155068     MEDLINE
DOCUMENT NUMBER:     PubMed ID: 6671136
TITLE:               Interaction of [3H] estradiol - and [3H]
                     monohydroxytamoxifen-estrogen receptor complexes with a
                     monoclonal antibody.
AUTHOR:              Tate A C; DeSombre E R; Greene G L; Jensen E V; Jordan V C
CONTRACT NUMBER:     P30-CA-14520 (NCI)
SOURCE:              Breast cancer research and treatment, (1983) 3 (3) 267-77.
                     Journal code: 8111104. ISSN: 0167-6806.
PUB. COUNTRY:        Netherlands
DOCUMENT TYPE:       Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:            English
FILE SEGMENT:        Priority Journals
ENTRY MONTH:         198405
ENTRY DATE:          Entered STN: 19900319
                     Last Updated on STN: 19970203
                     Entered Medline: 19840502

L7   ANSWER 2 OF 2     MEDLINE on STN
ACCESSION NUMBER:    84106548     MEDLINE
DOCUMENT NUMBER:     PubMed ID: 6692388
TITLE:               Differences between estrogen- and antiestrogen-estrogen
                     receptor complexes from human breast tumors identified with
                     an antibody raised against the estrogen receptor.
AUTHOR:              Tate A C; Greene G L; DeSombre E R; Jensen E V; Jordan V C
CONTRACT NUMBER:     P30-CA-14520 (NCI)
SOURCE:              Cancer research, (1984 Mar) 44 (3) 1012-8.
                     Journal code: 2984705R. ISSN: 0008-5472.
PUB. COUNTRY:        United States
DOCUMENT TYPE:       Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:            English
FILE SEGMENT:        Priority Journals
ENTRY MONTH:         198403
ENTRY DATE:          Entered STN: 19900319
                     Last Updated on STN: 19970203
                     Entered Medline: 19840323


=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.50       9.01

FILE 'CAPLUS' ENTERED AT 16:30:37 ON 10 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 9 Aug 2005 (20050809/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 4-HYDROXYTAMOXIFEN/CN
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L9 1273 L8

=> s breast or mammar?
62426 BREAST
523 BREASTS
62610 BREAST
(BREAST OR BREASTS)
77390 MAMMAR?
L10 101462 BREAST OR MAMMAR?

=> s density
269024 DENSITY
114999 DENSITIES
L11 358546 DENSITY
(DENSITY OR DENSITIES)

=> s l10 (S) l11
L12 235 L10 (S) L11

=> s l12 and l9
L13 1 L12 AND L9

=> s dens?
L14 496119 DENS?

=> s l14 and l10
L15 949 L14 AND L10

=> s l15 and l9
L16 3 L15 AND L9

=> d ibib 1-3

L16 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:531338 CAPLUS
DOCUMENT NUMBER: 141:65145
TITLE: Reduction of breast density with 4-hydroxy tamoxifen
INVENTOR(S): Bua, Jay
PATENT ASSIGNEE(S): Laboratoires Besins International, Fr.

SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054558	A2	20040701	WO 2003-EP15030	20031215
WO 2004054558	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004138314	A1	20040715	US 2003-734644	20031215
PRIORITY APPLN. INFO.:			US 2002-433958P P	20021218

L16 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1985:558391 CAPLUS
DOCUMENT NUMBER: 103:158391
TITLE: Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018
AUTHOR(S): Bronzert, Diane A.; Greene, Geoffrey L.; Lippman, Marc E.
CORPORATE SOURCE: Med. Branch, Natl. Cancer Inst., Bethesda, MD, 20205, USA
SOURCE: Endocrinology (1985), 117(4), 1409-17
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English

L16 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1985:481986 CAPLUS
DOCUMENT NUMBER: 103:81986
TITLE: Characterization of the subunit nature of nuclear estrogen receptors by chemical cross-linking and dense amino acid labeling
AUTHOR(S): Miller, Margaret Ann; Mullick, Alaka; Greene, Geoffrey L.; Katzenellenbogen, Benita S.
CORPORATE SOURCE: Dep. Physiol. Biophys., Univ. Illinois, Urbana, IL, 61801, USA
SOURCE: Endocrinology (1985), 117(2), 515-22
CODEN: ENDOAO; ISSN: 0013-7227
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 16:27:28 ON 10 AUG 2005)

FILE 'REGISTRY' ENTERED AT 16:27:48 ON 10 AUG 2005
E "4-HYDROXYTAMOXIFEN"/CN 25
L1 1 S E3

```
     FILE 'MEDLINE' ENTERED AT 16:28:48 ON 10 AUG 2005
L2            0 S L1
L3          666 S 4-HYDROXYTAMOXIFEN/CN
L4       233739 S BREAST OR MAMMAR?
L5       256821 S DENSITY
L6         1500 S L5 (S) L4
L7            2 S L6 AND L3

     FILE 'CAPLUS' ENTERED AT 16:30:37 ON 10 AUG 2005
                S 4-HYDROXYTAMOXIFEN/CN

     FILE 'REGISTRY' ENTERED AT 16:30:42 ON 10 AUG 2005
L8            1 S 4-HYDROXYTAMOXIFEN/CN

     FILE 'CAPLUS' ENTERED AT 16:30:43 ON 10 AUG 2005
L9         1273 S L8
L10      101462 S BREAST OR MAMMAR?
L11      358546 S DENSITY
L12         235 S L10 (S) L11
L13           1 S L12 AND L9
L14      496119 S DENS?
L15         949 S L14 AND L10
L16           3 S L15 AND L9

=> s cancer? or tumor? or neoplas?
        265968 CANCER?
        398752 TUMOR?
        417935 NEOPLAS?
L17     659727 CANCER? OR TUMOR? OR NEOPLAS?

=> s l17 and l10
L18      73400 L17 AND L10

=> s l18 (S) l10
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L18 (S) L10'
L19      73400 L18 (S) L10

=> s l17 (S) l10
L20      69226 L17 (S) L10

=> s l20 and l8
          1273 L8
L21        493 L20 AND L8

=> s l21 and percutan?
          8318 PERCUTAN?
L22          4 L21 AND PERCUTAN?

=> d ibib 1-22

L22  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        2004:857374  CAPLUS
DOCUMENT NUMBER:         141:325697
TITLE:                   Prevention and treatment of breast
                         cancer with 4-hydroxytamoxifen
INVENTOR(S):             Salin-Drouin, Dominique; Wepierre, Jacques; Rouanet,
                         Philippe
PATENT ASSIGNEE(S):      Laboratoires Besins International, Fr.
SOURCE:                  PCT Int. Appl., 46 pp.
                         CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087123	A1	20041014	WO 2003-EP15029	20031215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005031695	A1	20050210	US 2003-734638	20031215
PRIORITY APPLN. INFO.:			US 2003-458963P P	20030401

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:103660 CAPLUS
DOCUMENT NUMBER: 139:94939
TITLE: Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of normal human breast epithelial (HBE) cells in culture
AUTHOR(S): Malet, Catherine; Spritzer, Poli; Cumins, Caroline; Guillaumin, Delhy; Mauvais-Jarvis, Pierre; Kuttenn, Frederique
CORPORATE SOURCE: Department of Endocrinology and Reproductive Medicine, Hopital Necker, Paris, 75743, Fr.
SOURCE: Journal of Steroid Biochemistry and Molecular Biology (2003), Volume Date 2002, 82(4-5), 289-296
CODEN: JSBBEZ; ISSN: 0960-0760
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:935564 CAPLUS
DOCUMENT NUMBER: 124:44960
TITLE: Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue
AUTHOR(S): Pujol, Henri; Girault, Jacques; Rouanet, Philippe; Fournier, Sabine; Grenier, Jean; Simony, Joelle; Fourtillan, Jean-Bernard; Pujol, Jean-Louis
CORPORATE SOURCE: Cancer Institute, Montpellier University, Montpellier, F-34298, Fr.
SOURCE: Cancer Chemotherapy and Pharmacology (1995), 36(6), 493-8
CODEN: CCPHDZ; ISSN: 0344-5704
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

L22 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1985:620824 CAPLUS
DOCUMENT NUMBER: 103:220824
TITLE: Antiestrogen drug for percutaneous administration
INVENTOR(S): Mauvais Jarvis, Pierre; Kuttenn, Frederique
PATENT ASSIGNEE(S): Fr.
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8503228	A1	19850801	WO 1984-EP436	19841221
W: DK, JP, US				
RW: AT, BE, CH, DE, FR, GB, LU, NL, SE				
FR 2558373	A1	19850726	FR 1984-927	19840120
FR 2558373	B1	19870703		
EP 151326	A1	19850814	EP 1984-201920	19841219
EP 151326	B1	19890712		
R: IT				
EP 169214	A1	19860129	EP 1985-900469	19841221
EP 169214	B1	19920311		
R: AT, BE, CH, DE, FR, GB, LI, LU, NL, SE				
JP 61500914	T2	19860508	JP 1985-500495	19841221
JP 06067826	B4	19940831		
AT 73334	E	19920315	AT 1985-900469	19841221
US 4919937	A	19900424	US 1985-777786	19850913
DK 8504203	A	19850917	DK 1985-4203	19850917
DK 155143	B	19890220		
DK 155143	C	19890703		

PRIORITY APPLN. INFO.:			
FR 1984-927	A	19840120
EP 1985-900469	A	19841221
WO 1984-EP436	W	19841221

=> d kwic 4

L22 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
TI Antiestrogen drug for percutaneous administration
AB The title drug is a hydroalc. gel containing hydroxytamoxifen [1-(p-β-dimethylaminoethoxyphenyl)-trans-1-(p-hydroxyphenethylbut-1-ene](I) [68047-06-3] and progesterone [57-83-0]. I is used for the treatment of breast affections, particularly benign cancerous affections. Thus, a gel is given, containing progesterone 1.5, I 0.15, Carbopal 934 1, triethanolamine 1.5 g, EtOH 50 mL,. . .
ST topical antiestrogen pharmaceutical breast cancer
IT Neoplasm inhibitors
(antiestrogen pharmaceuticals, for percutaneous administration)
IT Estrogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, pharmaceuticals, for percutaneous administration)
IT Mammary gland
(neoplasm, treatment of, topical antiestrogen pharmaceuticals for)
IT 68047-06-3
RL: BIOL (Biological study)

```
        (antiestrogen pharmaceuticals containing, for percutaneous
        administration)
IT   57-83-0, biological studies
     RL: BIOL (Biological study)
        (pharmaceuticals containing hydroxytamoxifen and, for percutaneous
        administration)


=> file pctfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      28.29      42.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.73      -0.73

FILE 'PCTFULL' ENTERED AT 16:35:38 ON 10 AUG 2005
COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED:         9 AUG 2005      <20050809/UP>
MOST RECENT UPDATE WEEK:       200531        <200531/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s hydroxytamoxifen
L23        268 HYDROXYTAMOXIFEN

=> s cancer? or tumor? or neoplas?
         70495 CANCER?
         59135 TUMOR?
         20255 NEOPLAS?
L24      88096 CANCER? OR TUMOR? OR NEOPLAS?

=> s breast or mammar?
         28618 BREAST
          1130 BREASTS
         28849 BREAST
                 (BREAST OR BREASTS)
         13019 MAMMAR?
L25      34444 BREAST OR MAMMAR?

=> s l24 (S) l25
L26      26782 L24 (S) L25

=> s dens?
L27     209738 DENS?

=> s l27 and l26
L28      15333 L27 AND L26

=> s l28 and l23
L29        118 L28 AND L23

=> s l29 and dense
         29710 DENSE
           825 DENSES
         30063 DENSE
                 (DENSE OR DENSES)
L30         18 L29 AND DENSE
```

```
=> s l29 and density
        165069 DENSITY
         29501 DENSITIES
        170122 DENSITY
                 (DENSITY OR DENSITIES)
L31        111 L29 AND DENSITY

=> s l25 (S) densit?
        179779 DENSIT?
L32       1644 L25 (S) DENSIT?

=> s l32 and l23
L33         22 L32 AND L23

=> s l33 not py>2001
        398484 PY>2001
L34         10 L33 NOT PY>2001

=> d ibib 1-5

L34    ANSWER 1 OF 10    PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:       2001074377 PCTFULL  ED 20020822
TITLE (ENGLISH):        NON-MAMMALIAN GNRH ANALOGS AND USES THEREOF IN TUMOR
                        CELL GROWTH REGULATION AND CANCER THERAPY
TITLE (FRENCH):         ANALOGUES DE GNRH NON MAMMIFERE ET LEURS UTILISATIONS
                        POUR LA REGULATION DE LA CROISSANCE DE CELLULES
                        TUMORALES ET POUR LE TRAITEMENT DES CANCERS
INVENTOR(S):            SILER-KHODR, Theresa, M.;
                        KHODR, Gabriel, S.
PATENT ASSIGNEE(S):     SILER-KHODR, Theresa, M.;
                        KHODR, Gabriel, S.
DOCUMENT TYPE:          Patent
PATENT INFORMATION:
                        NUMBER             KIND     DATE
                        --------------------------------
                        WO 2001074377        A1 20011011
DESIGNATED STATES
       W:               AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
                        CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
                        IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
                        MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
                        TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL
                        SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE
                        DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
                        CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:      WO 2000-US26575      A  20000926
PRIORITY INFO.:         US 2000-09/540,685      20000331

L34    ANSWER 2 OF 10    PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:       2001063292 PCTFULL  ED 20020822
TITLE (ENGLISH):        COMPOSITIONS AND METHODS OF USE OF HET, A NOVEL
                        MODULATOR OF ESTROGEN ACTION
TITLE (FRENCH):         COMPOSITIONS ET UTILISATIONS DE HET, UN NOUVEAU
                        MODULATEUR DE L'ACTION OESTROGENIQUE
INVENTOR(S):            OESTERREICH, Steffi;
                        OSBORNE, C., Kent;
                        LEE, Adrian, V.;
                        FUQUA, Suzanne, A.W.
PATENT ASSIGNEE(S):     BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;
                        OESTERREICH, Steffi;
                        OSBORNE, C., Kent;
                        LEE, Adrian, V.;
```

FUQUA, Suzanne, A.W.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001063292	A2	20010830

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US6135	A	20010222
PRIORITY INFO.:	US 2000-60/184,097		20000222

L34 ANSWER 3 OF 10 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2001000245 PCTFULL ED 20020828
TITLE (ENGLISH): HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
TITLE (FRENCH): ANTICORPS ANTI-ERBB2 HUMANISES ET TRAITEMENT A L'AIDE DE CES ANTICORPS
INVENTOR(S): ADAMS, Camellia, W.;
PRESTA, Leonard, G.;
SLIWKOWSKY, Mark
PATENT ASSIGNEE(S): GENENTECH, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001000245	A2	20010104

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2000-US17366	A	20000623
PRIORITY INFO.:	US 1999-60/141,316		19990625

L34 ANSWER 4 OF 10 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2001000244 PCTFULL ED 20020828
TITLE (ENGLISH): METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
TITLE (FRENCH): TECHNIQUES DE TRAITEMENT UTILISANT DES CONJUGUES MAYTANSINOIDES-ANTICORPS ANTI-ERBB
INVENTOR(S): ERICKSON, Sharon;
SCHWALL, Ralph
PATENT ASSIGNEE(S): GENENTECH, INC.;
ERICKSON, Sharon;
SCHWALL, Ralph
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001000244	A2	20010104

DESIGNATED STATES

```
       W:              AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
                       CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
                       IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
                       MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
                       TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
                       SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
                       DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG
                       CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:     WO 2000-US17229      A  20000623
PRIORITY INFO.:        US 1999-60/141,316      19990625
                       US 2000-60/189,844      20000316

L34    ANSWER 5 OF 10    PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:      2001000238 PCTFULL  ED 20020828
TITLE (ENGLISH):       TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
TITLE (FRENCH):        TRAITEMENT DU CANCER DE LA PROSTATE A L'AIDE DES
                       ANTICORPS ANTI-ERBB2
INVENTOR(S):           AGUS, David, B.;
                       SCHER, Howard, I.;
                       SLIWKOWSKI, Mark, X.
PATENT ASSIGNEE(S):    GENENTECH, INC.;
                       SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
DOCUMENT TYPE:         Patent
PATENT INFORMATION:
                       NUMBER             KIND     DATE
                       --------------------------------
                       WO 2001000238        A1 20010104
DESIGNATED STATES
       W:              AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
                       CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
                       IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
                       MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
                       TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL
                       SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE
                       DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
                       CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:     WO 2000-US17423      A  20000623
PRIORITY INFO.:        US 1999-60/141,315      19990625


=> d his

     (FILE 'HOME' ENTERED AT 16:27:28 ON 10 AUG 2005)

     FILE 'REGISTRY' ENTERED AT 16:27:48 ON 10 AUG 2005
                E "4-HYDROXYTAMOXIFEN"/CN 25
L1              1 S E3

     FILE 'MEDLINE' ENTERED AT 16:28:48 ON 10 AUG 2005
L2              0 S L1
L3            666 S 4-HYDROXYTAMOXIFEN/CN
L4         233739 S BREAST OR MAMMAR?
L5         256821 S DENSITY
L6           1500 S L5 (S) L4
L7              2 S L6 AND L3

     FILE 'CAPLUS' ENTERED AT 16:30:37 ON 10 AUG 2005
                S 4-HYDROXYTAMOXIFEN/CN

     FILE 'REGISTRY' ENTERED AT 16:30:42 ON 10 AUG 2005
L8              1 S 4-HYDROXYTAMOXIFEN/CN
```

```
     FILE 'CAPLUS' ENTERED AT 16:30:43 ON 10 AUG 2005
L9          1273 S L8
L10       101462 S BREAST OR MAMMAR?
L11       358546 S DENSITY
L12          235 S L10 (S) L11
L13            1 S L12 AND L9
L14       496119 S DENS?
L15          949 S L14 AND L10
L16            3 S L15 AND L9
L17       659727 S CANCER? OR TUMOR? OR NEOPLAS?
L18        73400 S L17 AND L10
L19        73400 S L18 (S) L10
L20        69226 S L17 (S) L10
L21          493 S L20 AND L8
L22            4 S L21 AND PERCUTAN?

     FILE 'PCTFULL' ENTERED AT 16:35:38 ON 10 AUG 2005
L23          268 S HYDROXYTAMOXIFEN
L24        88096 S CANCER? OR TUMOR? OR NEOPLAS?
L25        34444 S BREAST OR MAMMAR?
L26        26782 S L24 (S) L25
L27       209738 S DENS?
L28        15333 S L27 AND L26
L29          118 S L28 AND L23
L30           18 S L29 AND DENSE
L31          111 S L29 AND DENSITY
L32         1644 S L25 (S) DENSIT?
L33           22 S L32 AND L23
L34           10 S L33 NOT PY>2001

=> s percutan?
L35       11391 PERCUTAN?

=> s l35 and l23
L36          17 L35 AND L23

=> s l36 and l26
L37          16 L36 AND L26

=> s l37 and densit?
         179779 DENSIT?
L38          11 L37 AND DENSIT?

=> s l23/ab
L39           1 (HYDROXYTAMOXIFEN/AB)

=> d ibib

L39    ANSWER 1 OF 1     PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:       1992004310 PCTFULL  ED 20020513
TITLE (ENGLISH):        TRIARYLETHYLENE CARBOXYLIC ACIDS WITH ESTROGENIC
                        ACTIVITY
TITLE (FRENCH):         ACIDES CARBOXYLIQUES DE TRIARYLETHYLENE A ACTIVITE
                        ESTROGENE
INVENTOR(S):            PETER, C., Ruenitz
PATENT ASSIGNEE(S):     UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:          Patent
PATENT INFORMATION:
                        NUMBER             KIND     DATE
                        ---------------------------------
                        WO 9204310           A1 19920319
```

```
DESIGNATED STATES
       W:               AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE
APPLICATION INFO.:      WO 1991-US6266       A  19910830
PRIORITY INFO.:         US 1990-579,398         19900907


=> d kwic

L39    ANSWER 1 OF 1     PCTFULL   COPYRIGHT 2005 Univentio on STN
ABEN .  .  .  the RCOOH and X moieties are either
       meta or para to the phenyl ethylene linkage. Examples of active
       compounds include 4-hydroxytamoxifen
       acid, 3-hydroxytamoxifen acid, 4-[1-(p-hydroxyphenyl)-2-phenyl-
       1-buten-yl]benzoic acid and
       4-[1-(p-hydroxyphenyl)-2-phenyl-1-buten-yl]phenylacetic acid.
       Compositions containing these
       triarylethylene carboxylic acids can be administered to patients to
       alleviate medical.  .  .
ABFR .  .  .  meta soit para
       par rapport a la liaison ethylene phenylique. On peut citer a titre
       d'exemples de composes actifs
       l'acide 4-hydroxytamoxifen, l'acide 3-hydroxytamoxifen
       , l'acide
       4-[1-(p-hydroxyphenyle)-2-phenyle-1-butene-yl]benzoique et l'acide
       4-[1-(p-hydroxyphenyle)-2-phenyle-1-butene-yl]phenylacetique. On peut
       administrer des compositions
       contenant ces acides carboxyliques de triarylethylene a des patients
       afin.  .  .


=> d his

     (FILE 'HOME' ENTERED AT 16:27:28 ON 10 AUG 2005)

     FILE 'REGISTRY' ENTERED AT 16:27:48 ON 10 AUG 2005
                E "4-HYDROXYTAMOXIFEN"/CN 25
L1              1 S E3

     FILE 'MEDLINE' ENTERED AT 16:28:48 ON 10 AUG 2005
L2              0 S L1
L3            666 S 4-HYDROXYTAMOXIFEN/CN
L4         233739 S BREAST OR MAMMAR?
L5         256821 S DENSITY
L6           1500 S L5 (S) L4
L7              2 S L6 AND L3

     FILE 'CAPLUS' ENTERED AT 16:30:37 ON 10 AUG 2005
                S 4-HYDROXYTAMOXIFEN/CN

     FILE 'REGISTRY' ENTERED AT 16:30:42 ON 10 AUG 2005
L8              1 S 4-HYDROXYTAMOXIFEN/CN

     FILE 'CAPLUS' ENTERED AT 16:30:43 ON 10 AUG 2005
L9           1273 S L8
L10        101462 S BREAST OR MAMMAR?
L11        358546 S DENSITY
L12           235 S L10 (S) L11
L13             1 S L12 AND L9
L14        496119 S DENS?
L15           949 S L14 AND L10
L16             3 S L15 AND L9
L17        659727 S CANCER? OR TUMOR? OR NEOPLAS?
```

```
L18       73400 S L17 AND L10
L19       73400 S L18 (S) L10
L20       69226 S L17 (S) L10
L21         493 S L20 AND L8
L22           4 S L21 AND PERCUTAN?

     FILE 'PCTFULL' ENTERED AT 16:35:38 ON 10 AUG 2005
L23         268 S HYDROXYTAMOXIFEN
L24       88096 S CANCER? OR TUMOR? OR NEOPLAS?
L25       34444 S BREAST OR MAMMAR?
L26       26782 S L24 (S) L25
L27      209738 S DENS?
L28       15333 S L27 AND L26
L29         118 S L28 AND L23
L30          18 S L29 AND DENSE
L31         111 S L29 AND DENSITY
L32        1644 S L25 (S) DENSIT?
L33          22 S L32 AND L23
L34          10 S L33 NOT PY>2001
L35       11391 S PERCUTAN?
L36          17 S L35 AND L23
L37          16 S L36 AND L26
L38          11 S L37 AND DENSIT?
L39           1 S L23/AB

=> s tamoxifen
          5058 TAMOXIFEN
            15 TAMOXIFENS
L40       5061 TAMOXIFEN
                 (TAMOXIFEN OR TAMOXIFENS)

=> s l40/ti
L41         25 (TAMOXIFEN/TI)

=> s l40/ab
            67 TAMOXIFEN/AB
             2 TAMOXIFENS/AB
L42         67 (TAMOXIFEN/AB)
                 ((TAMOXIFEN OR TAMOXIFENS)/AB)

=> s l42 or l47
L47 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l42 or l41
L43         70 L42 OR L41

=> s l43 and l26
L44         58 L43 AND L26

=> s l44 and percutan?
         11391 PERCUTAN?
L45          6 L44 AND PERCUTAN?

=> s l45 and densit?
        179779 DENSIT?
L46          6 L45 AND DENSIT?

=> s densit? (S) l25
        179779 DENSIT?
L47       1644 DENSIT? (S) L25
```

```
=> s l47 and l46
L48          2 L47 AND L46

=> d ibib 1-2

L48    ANSWER 1 OF 2     PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:        2004087123 PCTFULL  ED 20041019  EW 200442
TITLE (ENGLISH):         PREVENTION AND TREATMENT OF BREAST
                         CANCER WITH 4-HYDROXY TAMOXIFEN
TITLE (FRENCH):          PREVENTION ET TRAITEMENT DU CANCER DU SEIN A L'AIDE DE
                         4-HYDROXY TAMOXIFENE
INVENTOR(S):             SALIN-DROUIN, Dominique, 32, rue des Gatines, F-91370
                         Verrieres-le-Buisson, FR;
                         WEPIERRE, Jacques, 1, rue Valoise, F-77166 Grisy
                         Suisnes, FR;
                         ROUANET, Philippe, 154, rue des Quatre Seigneurs,
                         F-34090 Montpellier, FR
PATENT ASSIGNEE(S):      LABORATOIRES BESINS INTERNATIONAL, 5, rue du Bourg
                         l'Abbe, F-75003 Paris, FR [FR, FR]
AGENT:                   NARGOLWALLA, Cyra$, Cabinet Plasseraud, 65/67, rue de
                         la Victoire, F-75440 Paris Cedex 09$, FR
LANGUAGE OF FILING:      English
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER             KIND     DATE
                         ---------------------------------
                         WO 2004087123        A1 20041014
DESIGNATED STATES
       W:                AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
                         CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
                         IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
                         MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD
                         SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA
                         ZM ZW
       RW (ARIPO):       BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
       RW (EAPO):        AM AZ BY KG KZ MD RU TJ TM
       RW (EPO):         AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
                         MC NL PT RO SE SI SK TR
       RW (OAPI):        BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:       WO 2003-EP15029      A  20031215
PRIORITY INFO.:          US 2003-60/458,963      20030401

L48    ANSWER 2 OF 2     PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:        2004054558 PCTFULL  ED 20040707  EW 200427
TITLE (ENGLISH):         REDUCTION OF BREAST DENSITY WITH
                         4-HYDROXY TAMOXIFEN
TITLE (FRENCH):          REDUCTION DE LA DENSITE MAMMAIRE A L'AIDE DE
                         4-HYDROXY TAMOXIFENE
INVENTOR(S):             BUA, Jay, 3100 Saddle Crest Lane, Oakton, VA 22124, US
PATENT ASSIGNEE(S):      LABORATOIRES BESINS INTERNATIONAL, 5, rue du Bourg
                         l'Abbe, F-75003 Paris, FR [FR, FR]
AGENT:                   NARGOLWALLA, Cyra$, Cabinet Plasseraud, 65/67, rue de
                         la Victoire, F-75440 Paris Cedex 9$, FR
LANGUAGE OF FILING:      English
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER             KIND     DATE
                         ---------------------------------
                         WO 2004054558        A2 20040701
```

```
DESIGNATED STATES
       W:              AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
                       CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
                       IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
                       MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD
                       SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA
                       ZM ZW
       RW (ARIPO):     BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
       RW (EAPO):      AM AZ BY KG KZ MD RU TJ TM
       RW (EPO):       AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
                       MC NL PT RO SE SI SK TR
       RW (OAPI):      BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:     WO 2003-EP15030      A  20031215
PRIORITY INFO.:        US 2002-60/433,958      20021218


=> d his

     (FILE 'HOME' ENTERED AT 16:27:28 ON 10 AUG 2005)

     FILE 'REGISTRY' ENTERED AT 16:27:48 ON 10 AUG 2005
                E "4-HYDROXYTAMOXIFEN"/CN 25
L1             1 S E3

     FILE 'MEDLINE' ENTERED AT 16:28:48 ON 10 AUG 2005
L2             0 S L1
L3           666 S 4-HYDROXYTAMOXIFEN/CN
L4        233739 S BREAST OR MAMMAR?
L5        256821 S DENSITY
L6          1500 S L5 (S) L4
L7             2 S L6 AND L3

     FILE 'CAPLUS' ENTERED AT 16:30:37 ON 10 AUG 2005
                S 4-HYDROXYTAMOXIFEN/CN

     FILE 'REGISTRY' ENTERED AT 16:30:42 ON 10 AUG 2005
L8             1 S 4-HYDROXYTAMOXIFEN/CN

     FILE 'CAPLUS' ENTERED AT 16:30:43 ON 10 AUG 2005
L9          1273 S L8
L10       101462 S BREAST OR MAMMAR?
L11       358546 S DENSITY
L12          235 S L10 (S) L11
L13            1 S L12 AND L9
L14       496119 S DENS?
L15          949 S L14 AND L10
L16            3 S L15 AND L9
L17       659727 S CANCER? OR TUMOR? OR NEOPLAS?
L18        73400 S L17 AND L10
L19        73400 S L18 (S) L10
L20        69226 S L17 (S) L10
L21          493 S L20 AND L8
L22            4 S L21 AND PERCUTAN?

     FILE 'PCTFULL' ENTERED AT 16:35:38 ON 10 AUG 2005
L23          268 S HYDROXYTAMOXIFEN
L24        88096 S CANCER? OR TUMOR? OR NEOPLAS?
L25        34444 S BREAST OR MAMMAR?
L26        26782 S L24 (S) L25
L27       209738 S DENS?
L28        15333 S L27 AND L26
L29          118 S L28 AND L23
```

```
L30          18 S L29 AND DENSE
L31         111 S L29 AND DENSITY
L32        1644 S L25 (S) DENSIT?
L33          22 S L32 AND L23
L34          10 S L33 NOT PY>2001
L35       11391 S PERCUTAN?
L36          17 S L35 AND L23
L37          16 S L36 AND L26
L38          11 S L37 AND DENSIT?
L39           1 S L23/AB
L40        5061 S TAMOXIFEN
L41          25 S L40/TI
L42          67 S L40/AB
L43          70 S L42 OR L41
L44          58 S L43 AND L26
L45           6 S L44 AND PERCUTAN?
L46           6 S L45 AND DENSIT?
L47        1644 S DENSIT? (S) L25
L48           2 S L47 AND L46

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      19.43      62.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -0.73

STN INTERNATIONAL LOGOFF AT 16:42:33 ON 10 AUG 2005


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 28  PATDPAFULL - New display fields provide for legal status
```

```
                  data from INPADOC
 NEWS  4  FEB 28  BABS - Current-awareness alerts (SDIs) available
 NEWS  5  MAR 02  GBFULL: New full-text patent database on STN
 NEWS  6  MAR 03  REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  7  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 22  KOREAPAT now updated monthly; patent information enhanced
 NEWS  9  MAR 22  Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  10 MAR 22  PATDPASPC - New patent database available
 NEWS  11 MAR 22  REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  12 APR 04  EPFULL enhanced with additional patent information and new
                  fields
 NEWS  13 APR 04  EMBASE - Database reloaded and enhanced
 NEWS  14 APR 18  New CAS Information Use Policies available online
 NEWS  15 APR 25  Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
 NEWS  16 APR 28  Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus
 NEWS  17 MAY 23  GBFULL enhanced with patent drawing images
 NEWS  18 MAY 23  REGISTRY has been enhanced with source information from
                  CHEMCATS
 NEWS  19 JUN 06  The Analysis Edition of STN Express with Discover!
                  (Version 8.0 for Windows) now available
 NEWS  20 JUN 13  RUSSIAPAT: New full-text patent database on STN
 NEWS  21 JUN 13  FRFULL enhanced with patent drawing images
 NEWS  22 JUN 27  MARPAT displays enhanced with expanded G-group definitions
                  and text labels
 NEWS  23 JUL 01  MEDICONF removed from STN
 NEWS  24 JUL 07  STN Patent Forums to be held in July 2005
 NEWS  25 JUL 13  SCISEARCH reloaded
 NEWS  26 JUL 20  Powerful new interactive analysis and visualization software,
                  STN AnaVist, now available

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:51:47 ON 11 AUG 2005

=> file pctfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21
```

```
FILE 'PCTFULL' ENTERED AT 08:52:01 ON 11 AUG 2005
COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED:         9 AUG 2005      <20050809/UP>
MOST RECENT UPDATE WEEK:       200531        <200531/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s hydroxytamoxifen or (hyrdroxy tamoxifen)
            268 HYDROXYTAMOXIFEN
             13 HYRDROXY
           5058 TAMOXIFEN
             15 TAMOXIFENS
           5061 TAMOXIFEN
                  (TAMOXIFEN OR TAMOXIFENS)
              0 HYRDROXY TAMOXIFEN
                  (HYRDROXY(W)TAMOXIFEN)
L1          268 HYDROXYTAMOXIFEN OR (HYRDROXY TAMOXIFEN)

=> s tamoxifen
           5058 TAMOXIFEN
             15 TAMOXIFENS
L2         5061 TAMOXIFEN
                  (TAMOXIFEN OR TAMOXIFENS)

=> s l2/ab
             67 TAMOXIFEN/AB
              2 TAMOXIFENS/AB
L3           67 (TAMOXIFEN/AB)
                  ((TAMOXIFEN OR TAMOXIFENS)/AB)

=> s l2/ti
L4           25 (TAMOXIFEN/TI)

=> s l4 or l2
L5         5061 L4 OR L2

=> s l4 or l3
L6           70 L4 OR L3

=> s breast or mammar
=> s breast or mammar?
          28618 BREAST
           1130 BREASTS
          28849 BREAST
                  (BREAST OR BREASTS)
          13019 MAMMAR?
L7        34444 BREAST OR MAMMAR?

=> s cancer? or tumor? or neoplas?
          70495 CANCER?
          59135 TUMOR?
          20255 NEOPLAS?
L8        88096 CANCER? OR TUMOR? OR NEOPLAS?

=> s l7/ab
           1789 BREAST/AB
             86 BREASTS/AB
           1818 BREAST/AB
                  ((BREAST OR BREASTS)/AB)
            241 MAMMAR?/AB
```

```
L9        2015 (BREAST/AB OR MAMMAR?/AB)

=> s l9 and l8
L10       1529 L9 AND L8

=> s percutaneous? or topical?
         10644 PERCUTANEOUS?
         49656 TOPICAL?
L11      57173 PERCUTANEOUS? OR TOPICAL?

=> s l11 and l10
L12        498 L11 AND L10

=> d his

     (FILE 'HOME' ENTERED AT 08:51:47 ON 11 AUG 2005)

     FILE 'PCTFULL' ENTERED AT 08:52:01 ON 11 AUG 2005
L1          268 S HYDROXYTAMOXIFEN OR (HYRDROXY TAMOXIFEN)
L2         5061 S TAMOXIFEN
L3           67 S L2/AB
L4           25 S L2/TI
L5         5061 S L4 OR L2
L6           70 S L4 OR L3
L7        34444 S BREAST OR MAMMAR?
L8        88096 S CANCER? OR TUMOR? OR NEOPLAS?
L9         2015 S L7/AB
L10        1529 S L9 AND L8
L11       57173 S PERCUTANEOUS? OR TOPICAL?
L12         498 S L11 AND L10

=> s l12 and l6
L13         10 L12 AND L6

=> s l13 and l1
L14          5 L13 AND L1

=> s l14 not py>2002
        294498 PY>2002
L15          1 L14 NOT PY>2002

=> d ibib 1

L15    ANSWER 1 OF 1     PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:       2001063292 PCTFULL  ED 20020822
TITLE (ENGLISH):        COMPOSITIONS AND METHODS OF USE OF HET, A NOVEL
                        MODULATOR OF ESTROGEN ACTION
TITLE (FRENCH):         COMPOSITIONS ET UTILISATIONS DE HET, UN NOUVEAU
                        MODULATEUR DE L'ACTION OESTROGENIQUE
INVENTOR(S):            OESTERREICH, Steffi;
                        OSBORNE, C., Kent;
                        LEE, Adrian, V.;
                        FUQUA, Suzanne, A.W.
PATENT ASSIGNEE(S):     BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;
                        OESTERREICH, Steffi;
                        OSBORNE, C., Kent;
                        LEE, Adrian, V.;
                        FUQUA, Suzanne, A.W.
DOCUMENT TYPE:          Patent
PATENT INFORMATION:
                        NUMBER             KIND     DATE
                        --------------------------------
```

	WO 2001063292	A2 20010830
DESIGNATED STATES		
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU	
	CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN	
	IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK	
	MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM	
	TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD	
	SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY	
	DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF	
	CG CI CM GA GN GW ML MR NE SN TD TG	
APPLICATION INFO.:	WO 2001-US6135	A 20010222
PRIORITY INFO.:	US 2000-60/184,097	20000222

=> d abs

L15 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2005 Univentio on STN

ABEN Estrogen Receptor; Nuclear Matrix Protein HET/SAF-B; Transcription; Repression; Antiestrogen; Tamoxifen. Disclosed are methods for the detection of tumor cells, in particular human breast cancer cells. Genetic and antibody probes and methods useful in determining the presence of and monitoring tumor cell proliferation are also described. The methods involve determining HET polypeptide expression, mRNA levels or loss of heterozygosity at human chromosomal locus 19p13 as a measure of tumor cell malignancy. These methods are also of use in distinguishing breast cancers that are resistant to estrogen antagonists, such as tamoxifen, from estrogen antagonist sensitive tumors. Also described are procedures for transforming cells with HET gene containing vectors that express HET polypeptide. Such procedures may be of use in converting tamoxifen-resistant tumors into tamoxifen -sensitive tumors.

ABFR Mots-cles : recepteur d'oestrogene ; proteine de matrice nucleaire HET/SAF-B ; transcription, repression; anti-oestrogene; tamoxifene L'invention concerne des procedes de detection de cellules tumorales, en particulier de cellules du cancer du sein humain. Elle concerne en outre des sondes genetiques et des sondes d'anticorps ainsi que des procedes servant a determiner la presence d'une proliferation de cellules tumorales et des surveiller celle-ci. Ces procedes consistent a mesurer l'expression du polypeptide HET, les taux d'ARNm ou la perte du caractere heterozygote dans le locus chromosomique 19p13, afin de determiner le degre de malignite des cellules tumorales. Ces procedes permettent en outre de distinguer les cancers du sein resistants aux antagonistes de l'oestrogene tels que le tamoxifene, des tumeurs sensibles aux antagonistes de l'oestrogene. L'invention concerne en outre des procedures consistant a transformer des cellules avec des vecteurs contenant un gene HET exprimant le polypeptide HET. Ces procedures peuvent etre utiles pour convertir les tumeurs resistantes au tamoxifene en tumeurs sensibles au tamoxifene.

=> d kwic

L15 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2005 Univentio on STN

ABEN Estrogen Receptor; Nuclear Matrix Protein HET/SAF-B; Transcription; Repression; Antiestrogen; Tamoxifen. Disclosed are methods for the detection of tumor cells, in particular human breast cancer cells. Genetic and antibody probes and methods useful in determining the presence of and monitoring tumor cell proliferation are also described. The methods involve

determining HET polypeptide expression, mRNA levels or loss of heterozygosity at human chromosomal locus 19p13 as a measure of tumor cell malignancy. These methods are also of use in distinguishing breast cancers that are resistant to estrogen antagonists, such as tamoxifen, from estrogen antagonist sensitive tumors. Also described are procedures for transforming cells with HET gene containing vectors that express HET polypeptide. Such procedures may be of use in converting tamoxifen-resistant tumors into tamoxifen -sensitive tumors.

ABFR . . . d'oestrogene ; proteine de matrice nucleaire HET/SAF-B ; transcription, repression; anti-oestrogene; tamoxifene L'invention concerne des procedes de detection de cellules tumorales, en particulier de cellules du cancer du sein humain. Elle concerne en outre des sondes genetiques et des sondes d'anticorps ainsi que des procedes servant a determiner la presence d'une proliferation de cellules tumorales et des surveiller celle-ci. Ces procedes consistent a mesurer l'expression du polypeptide HET, les taux d'ARNm ou la perte du caractere heterozygote dans le locus chromosomique 19p13, afin de determiner le degre de malignite des cellules tumorales . Ces procedes permettent en outre de distinguer les cancers du sein resistants aux antagonistes de l'oestrogene tels que le tamoxifene, des tumeurs sensibles aux antagonistes de l'oestrogene. L'invention concerne. . .

DETD 1.1 Field of the Invention
The present invention relates generally to cancer biology. In particular, it
concerns novel methods and compositions for modulating estrogen actions. The
present invention further relates to detection, diagnosis and prognosis of breast cancer
and the identification of tamoxifen-resistant breast cancers. Another aspect of the
present invention relates to gene therapy for altering the phenotype of tumor cells.

More particularly, it concerns use of expression vectors comprising an BET gene to
increase the sensitivity of the tumor cell to estrogen antagonists, or to decrease the
sensitivity of the tumor cell to estrogen and estrogen agonists.

Hsp27 plays a role in both growth and drug resistance of human breast cancer
cells in culture (Oesterreich et aL, 1993). Hsp27 has been found to contribute to
increased drug resistance in CHO cells (Lavoie et al., 1993), colon cancer cells
(Garrido et aL, 1996), and testis cancer cells (Richards et al., 1996). Elevated hsp27
levels also correlate with increased invasion of human breast cancer cells (Lemieux et
al., 1996). Hsp 27 is not an independent prognostic marker for breast cancer
(Oesterreich et al., 1996b). However, hsp27 predicts a significantly worse outcome in
10, a subset of ER-positive/untreated breast cancer patients (Oesterreich et aL, 1996b).

Expression of hsp27 is strongly correlated with the expression of ER in

breast tumors
.(Oesterreich et aI., 1996b). Several groups have tried to decrease the expression of
heat shock proteins in order to circumvent drug resistance in tumors. For example, the
antiestrogen toremifene (Mahvi et aL, 1996) and the bioflavonoid quercetin (Sliutz et
1 5 aL, 1996) both decrease hsp. . .

Current therapies for breast cancer are targeted, at least in part, to the estrogen
receptor. A group of compounds known as selective estrogen receptor modulators
(SERMs) may be used in the prevention and treatment of breast cancer (Minton,
1999). These compounds mediate agonist or antagonist effects of estrogen on the ER.

However, certain breast cancers are antiestrogen resistant, and it is not unusual, for
resistance to develop following antiestrogen therapy. A need exists in the art to
distinguish those tumors that are sensitive to antiestrogens from those that are
resistant. A method of converting antiestrogen-resistant tumors to antiestrogen-
sensitive tumors would be of great benefit for treatment of breast cancer.

. . .
THE INVENTION
The present invention resolves a need in the art for a diagnostic method to
differentiate between antiestrogen-resistant and antiestrogen-sensitive breast tumors.

Also provided are compositions and methods of use in converting antiestrogen-
resistant to antiestrogen-sensitive tumors, by administering expression vectors
comprising an BET coding sequence. Specific examples include compositions and
methods of use in differentiating antiestrogen-resistant and antiestrogen-sensitive
tumors and in converting antiestrogen-resistant to antiestrogen-sensitive tumors.

Specific antiestrogens that are within the context of the invention include the
nonsteroidal compounds Tamoxifen, Toremifene, Idoxifene, Droloxifene, TAT-59,
Zindoxifene, Trioxifene, and. . . the steroidal antiestrogens ICI 182,780 (FASLODEXTm) and EM Tamoxifen is a particularly well-known estrogen antagonist that exhibits efficacy for treatment of breast cancer. Some of the
other nonsteroidal compounds, e.g. TAT-59, are metabolized into an active metabolite
of Tamoxifen or are analogues of Tamoxifen, e.g.. . .

. . .
linked to the region encoding said protein, under conditions effective for
the uptake and expression of said nucleic acid by said tumor cell, wherein said cell is

converted from a phenotype displaying normal steroid hormone receptor activity to
one displaying reduced steroid hormone receptor. . .
. . .
Of course, as detailed herein, some of the primary embodiments of the present
invention entail the diagnosing and treatment of breast cancer
. Exemplary forms of
breast cancer that may be diagnosed and/or treated according
to the invention include
infiltrating duct carcinoma, lobular carcinoma, medullary carcinoma, mucinous
carcinoma, tubular carcinoma,. . .

In some embodiments, the invention relates to methods for detecting resistance
to antiestrogens in breast cancer cells, comprising: a)
obtaining a sample suspected of
containing breast cancer cells; b) contacting said sample with
an antibody that
specifically binds to an BET polypeptide under conditions effective to bind said
antibody. . .
. . .
Western blotting, ELISA. Northern blotting, slot blotting, dot blotting and/or DNA chip assay
Alternative embodiments include methods for predicting antiestrogen resistance
in breast cancer cells, comprising: a) measuring the amount of
BET gene product in a
sample containing breast cancer cells; and b) comparing the
amount of BET gene
product present in said sample with the amount of BET gene product in samples
selected from patients with antiestrogen-resistant and
antiestrogen-sensitive breast
cancers. Exemplary antiestrogens can be selected from the
group consisting of
Tamoxifen, Torenffene, Idoxifene, Droloxifene, TAT-59, Zindoxifene, Trioxifene,
Raloxifene, ICI 182,780 and EM. . .

The invention also relates to method for predicting antiestrogen resistance in
breast cancer cells, comprising: a) obtaining a breast
cancer cell sample and a normal
cell sample from the same individual; b) amplifying chromosomal DNA from said
breast cancer and normal cell samples using primers selected
to amplify a chromosomal
locus comprising the BET gene; and c) comparing the amplification products from
said breast cancer and normal cells, wherein loss of
heterozygosity (LOH) at said locus
indicated by an amplification product present in the normal cell and missing in the
breast cancer cell is indicative of antiestrogen resistance in
said breast cancer cell.

In a further embodiment, the invention anticipates methods for detecting anti-
estrogen resistance in breast cancer cells, comprising: a)

obtaining a sample suspected
of containing breast cancer cells; b) measuring the amount of
BET gene product in
said sample,] wherein said BET gen& product is a molecule. . . in
the amount of BET gene product in said
sample compared with the amount in normal cells indicates anti-estrogen
resistance of
breast cancer cells.

The invention further encompasses methods of malignant breast
cancer
diagnosis, comprising determining loss of heterozygosity (LOH) at a
chromosomal
locus comprising the BET gene, wherein LOH at said locus is indicative
of
antiestrogen resistance in breast cancer cells. Likewise, the
invention encompasses
methods of determining likelihood of survival for a breast tumor
subject, comprising
determining loss of heterozygosity (LOH) at a chromosomal locus
comprising the BET
gene in a breast tumor cell sample from said subject, wherein
LOH at said locus is
associated with a decreased probability of survival.

The invention further contemplates methods for altering the phenotype of
a
breast tumor cell comprising contacting the cell with a
nucleic acid comprising (i) a
DNA sequence encoding a BET protein and (ii) a promoter active in said
breast tumor
cell, wherein said promoter is operably linked to the region encoding
said protein,
under conditions effective for the uptake and expression of said nucleic
acid by said
tumor cell. In some exemplary embodiments, the BET protein has
the amino acid
sequence of SEQ ID NO:2. For example, the breast tumor cell
may be converted from
a phenotype resistant to antiestrogen to a phenotype sensitive to
antiestrogen. In this
case, the antiestrogen may. . .

FIG. 6A and FIG. 611. BET/SAF-B expression is decreased in antiestrogen-
resistant xenograft tumors.

FIG. 7 illustrates a human metaphase spread with the BET PI probe
fluorescently
labeling both chromosome 19 homologs at 19pl3 >pl3.3
FIG. 8 shows an LOH analysis at human chromosomal locus 19p13 of breast
tumor
specimens. Breast biopsy DNA (normal and tumor) was analyzed
using PCRTm based
microsatellite markers corresponding to 19-pter (Genethon, see Gyapay et
aL, 1994).

FIG. 9 illustrates HET expression in primary breast cancers.
Frozen tumor powder
was homogenized in 5% SDS, and 25]ig protein was resolved on 7.5% PAGE.
After
transferring onto nitrocellulose, BET was detected. . .

FIG. 11 shows that transient transfection of antisense BET into 293 cancer cells
causes an increased rate of cell division, as measured by [3 H]-thymidine incorporation
into DNA. Cells were transfected with 0.02, 0.2. . .
. . .
activity, it is meant that the
molecule in question has the ability to inhibit cell transformation, or to prevent
metastasis or invasive tumor growth. Other phenotypes that may be regulated by the
normal BET gene product are angiogenesis, cell adhesion, migration, cell-to-cell
signaling, cell growth,. . .

The term tumor suppressor is well-known to those of skill in the art.

Examples of other tumors suppressors are p53, Rb and p16, to name a few. While
these molecules are structurally distinct, they form a group of functionally-related
molecules, of which BET is a member. The uses for which these other tumor
suppressors now are being exploited are equally applicable here.

The inventors have discovered that the gene encoding the BET protein (the
1 5 HET gene) is a tumor suppressor gene. BET has been mapped to chromosomal locus
19pl3 pl3 Using LOH technology, it was found that this locus is lost in 50-60%
of breast cancer patients, which is higher than the LOH described for any other tumor
suppressor gene described to date (e.g., p53, Rb).
. . .
the entire BET molecule, the present invention also relates to fragments of the polypeptide that may or may not retain the tumor suppressing (or
other) activity of BET. Fragments including the N-terminus of the molecule may be
generated by genetic engineering of translation stop. . .
. . .
Encoding HET
Nucleic acids according to the present invention may encode an entire BET
gene, a domain of BET that expresses a tumor suppressing function, or any other
fragment of the BET sequences set forth herein. The nucleic acid may be derived from
genomic DNA. . .

4 5 Antisense Constructs
In some cases, mutant tumor suppressors may not be non-functional. Rather,
they may have aberrant functions that cannot be overcome by replacement gene
therapy, even where the. . .

4 6 Ribozymes
Another approach for addressing the dominant negative mutant tumor

suppressor is through the use of ribozymes. Although proteins traditionally have been
used for catalysis of nucleic acids, another class of macromolecules. . .
. . .
I (TN 1)
Platelet-Derived Growth Factor
Duchenne Muscular Dystrophy
SV40
ENHA-NCER/PROMOTER
Polyoma,
Retroviruses
PapiRoma, Virus
Hepatitis B Virus
Human Immunodeficiency Virus
Cytomegalovirus
TABLE3
Element Inducer
Mr II Phorbol Ester (TPA)
Heavy metals
MMTV (mouse mammary tumor Glucocorticoids
virus)
P-Interferon poly(rl)X
poly(rc)
Adenovirus 5 E2 Ela
c-jun Phorbol Ester (TPA), H202
Collagenase Phorbol Ester (TPA)
Stromelysin Phorbol Ester (TPA), IOL-1
SV40 Phorbol Ester (TPA)
Murine NIX. . . Interferon, Newcastle Disease Virus
GRP78 Gene A23187
a Macroglobuhn IL-6
Vitnentin Serum
MHC Class I Gene H-2kB Interferon
HSP70 Ela, SV40 Large T Antigen
Proliferin Phorbol Ester-TPA
Tumor Necrosis Factor FMA
Thyroid Stimulating Hormone a Thyroid Hon-none
Gene
Insulin E Box Glucose
Where a cDNA insert is employed, typically one will typically. . .
. . .
that a
nucleic acid encoding a BET gene also may be specifically delivered into a cell type
such as lung, epithelial, or tumor cells, by any number of receptor-ligand systems with
or without liposomes. For example, epidermal growth factor (EGF) may be used as
the receptor for mediated delivery of a nucleic acid encoding a gene in many tumor
cells that exhibit upregulation of EGF receptor. Mannose can be used to target the
mannose receptor on liver cells. Also, antibodies to. . .
. . .
most widely used means of large scale production of cells and cell products. However, suspension cultured cells have limitations, such as tumorigenic
potential and lower protein production than adherent T-cells.
. . .
of the type that was used to provide the somatic
and myeloma cells for the original fusion. The injected animal develops

tumors
secreting the specific monoclonal antibody produced by the fused cell hybrid. The
body fluids of the animal, such as serum or ascites. . .

4.4 Diagnosing Cancers Involving HET
The present inventors have determined that alterations in BET are'associated
with breast cancer and may be associated with other malignancies. Therefore, BET
and the corresponding gene may be employed as a diagnostic or prognostic indicator
of cancer. More specifically, point mutations, deletions, insertions, allelic loss, or
regulatory perturbations relating to BET may cause cancer or promote cancer
development, cause or promote tumor progression at a primary site, and/or cause or
promote metastasis. Other phenomena associated with malignancy that may be
affected by BET expression. . .

Another aspect of the present invention concerns distinguishing tamoxifen-
sensitive from tamoxifen-resistant cancers, more particularly breast cancers.

Tamoxifen resistance is associated with decreased levels of BET gene products in
breast cancer cells. Determination of BET expression levels, by assay of BET mRNA
or protein, may be used to distinguish tumors that are resistant to estrogen antagonists
(such as tamoxifen) from tumors that are sensitive to estrogen antagonists.

Alternatively, LOH assay may be used to identify tumors that have lost an allele of the
BET gene. Such tumors are expected to show a decreased expression of HET gene
product.
. . .
alterations in the expressed product in a
biological sample. In particular, the present invention relates to the diagnosis or
prognosis of breast cancer.
. . .
a patient with a
sufficiently large reference group of normal patients and patients that have BET-
related pathologies, such as malignant breast tumors. In this way, it is possible to
correlate the amount or type of BET detected (for example, mutant or truncated BET
polypeptides) with various clinical states. In particular applications, such as breast
cancers, it is contemplated that different levels of progression of breast cancer may be
identified. In further embodiments, the sensitivity of tumors to estrogen antagonists,
such as tamoxifen, may be determined.

5 The amplified sequences may then be identified and quantitated. The presence of the
BET gene or mutants thereof may be used in the methods disclosed herein to
determine degree of malignancy, cell tumorigenicity, and potential prognosis/diagnosis
of cancers such as breast cancers.

. . .
as ELISA and
Western blotting. This may provide a screen for the presence or absence of
malignancy, as a predictor of future cancer, or to distinguish tamoxifen-resistant from
tamoxifen-sensitive tumors.

. . .
or inhibition or stimulation of cell-to-cell signaling,
growth, metastasis, cell division, cell migration, soft agar colony formation, contact
inhibition, invasiveness, angiogenesis, apoptosis, tumor progression or other malignant
phenotype. Preferred embodiments include assay of cell replication by incorporation of
radiolabeled thymidine or colony formation. A preferred. . .

. . .
the use of various animal models. By
developing or isolating mutant cells lines that fail to express normal BET, one can
generate cancer models in mice that will be predictive of cancers in humans and other
mammals. These models may employ the orthotopic or systemic administration of
tumor cells to mimic primary and/or metastatic cancers
. Alternatively, one may induce
cancers in animals by providing agents known to be responsible for certain events
associated with malignant transformation and/or tumor progression. Finally,
transgenic animals (discussed below) that lack a wild-type BET may be utilized as
models for cancer development and treatment.

. . .
any
route that could be utilized for clinical or non-clinical purposes, including but not
limited to oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration
may be by intratracheal instillation, bronchial instillation, intradermal, subcutaneous,
intramuscular, intraperitoneal or intravenous injection. Specifically contemplated are
systemic intravenous injection, regional. . .

. . .
a compound in vivo may involve a variety of
different criteria. Such criteria include, but are not limited to, survival, reduction of
tumor burden or mass, arrest or slowing of tumor progression, elimination of tumors,
inhibition or prevention of metastasis, increased activity level, improvement in immune
effector function and improved food intake.

4.6 Methods for Treating HET Related Malignancies

The present invention also contemplates, in another embodiment, the treatment of cancer. The types of cancer that may be treated, according to the present invention, are limited only by the involvement of BET. By involvement is meant that, it is not even a requirement that BET be mutated or abnormal - the overexpression of this tumor suppressor may actually overcome other lesions within the cell. Thus, it is contemplated that a wide variety of tumors may be treated using BET therapy.

In many contexts, it is not necessary that the tumor cell be killed or induced to undergo normal cell death or apoptosis. Rather, to accomplish a meaningful treatment, all that is required is that the tumor growth be slowed to some degree. It may be that the tumor growth is completely blocked, however, or that some tumor regression is achieved. Clinical terminology such as remission and reduction of tumor burden also are contemplated given their normal usage.

In further embodiments, the treatment of cancer with BET therapy may be directed towards malignancies. that are or are likely to become resistant to therapeutic compounds. In one embodiment, BET therapy may be used to treat cancer cells that have become resistant to compounds that inhibit steroid receptors. In another embodiment, BET therapy may be used to treat cells. . . . . the therapeutic embodiments contemplated by the present inventors is the intervention, at the molecular level, in the events involved in the tumorigenesis of some cancers. Specifically, the present inventors intend to provide, to a cancer cell, an expression construct capable of providing BET to that cell. Any of the gene sequence variants discussed above which would encode. . .

Various routes are contemplated for various tumor types. The section below on routes contains an extensive list of possible routes. For practically any tumor, systemic delivery is contemplated. This will prove especially important for attacking microscopic or metastatic cancer. Where discrete tumor mass may be identified, a variety of direct, local and regional approaches may be taken. For example, the tumor may be injected directly with the expression vector. A tumor bed may be treated prior to, during or after resection. Following resection, one generally will deliver the vector by a catheter left in place following surgery. One may utilize the tumor vasculature to introduce the vector into the tumor by injecting a supporting vein or artery. A more

distal blood supply route also may be utilized.

. . .

different embodiment, ex vivo gene therapy is contemplated. This approach is particularly suited, although not limited, to treatment of bone marrow associated cancers. In an ex vivo embodiment, cells fromthe patient are removed and maintained outside the body for at least some period of time. During this period, a therapy is delivered, after which the cells are reintroduced into the patient. Preferably, any tumor cells in the sample have been killed.

. . .

own bone marrow donor. Thus, a normally lethal dose of irradiation or chemotherapeutic may be delivered to the patient to HI tumor cells, and the bone marrow repopulated with the patient's own cells that have been maintained (and perhaps expanded) ex vivo. Because bone marrow is often contaminated with tumor cells, it is desirable to purge the bone marrow of these cells. Use of gene therapy to accomplish this goal is yet. . .

4 2 Immunotherapies

Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing.. . . targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.

. . .

part of a combined therapy, in conjunction with BET-targeted gene therapy. The general approach for combined therapy is discussed below. Generally, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present invention. Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, MUG, sialyl Lewis antigen, MucA,, MucB, PLAP, estrogen receptor, larninin receptor, erb B and. . .

4 3 Combined Therapy with Immunotherapy, Traditional Chemo- or Radiotherapy

1 5 Tumor cell resistance to DNA damaging agents represents a major problem in clinical oncology. One goal of current cancer research is to find ways to improve the

efficacy of cherno- and radiotherapy. One way is by combining such traditional therapies
with gene therapy. For example, the herpes simplex-thyraidine kinase (HS-tk) gene, when
delivered to brain tumors by a retroviral vector system, successfully induced susceptibility
to the antiviral agent ganciclovir (Culver et al., 1992). In the context of. . .

To HI cells, inhibit cell growth, inhibit metastasis, inhibit angiogenesis or otherwise
reverse or reduce the malignant phenotype of tumor cells, using the methods and
compositions of the present invention, one would generally contact a target cell with an
BET expression construct. . .

I In treating cancer according to the invention, one would contact the tumor cells
withan agent in addition to the expression construct. This may be achieved by irradiating
<------User Break------>

UV-light, y-rays or even
I 0 microwaves. Alternatively, the tumor cells may be contacted with the agent by
administering to the subject a therapeutically effective amount of a pharmaceutical
composition comprising a. . .

```
=> d his

     (FILE 'HOME' ENTERED AT 08:51:47 ON 11 AUG 2005)

     FILE 'PCTFULL' ENTERED AT 08:52:01 ON 11 AUG 2005
L1           268 S HYDROXYTAMOXIFEN OR (HYRDROXY TAMOXIFEN)
L2          5061 S TAMOXIFEN
L3            67 S L2/AB
L4            25 S L2/TI
L5          5061 S L4 OR L2
L6            70 S L4 OR L3
L7         34444 S BREAST OR MAMMAR?
L8         88096 S CANCER? OR TUMOR? OR NEOPLAS?
L9          2015 S L7/AB
L10         1529 S L9 AND L8
L11        57173 S PERCUTANEOUS? OR TOPICAL?
L12          498 S L11 AND L10
L13           10 S L12 AND L6
L14            5 S L13 AND L1
L15            1 S L14 NOT PY>2002

=> s l14 not py>2003
        184564 PY>2003
L16           2 L14 NOT PY>2003

=> d ibib 1

L16    ANSWER 1 OF 2     PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:       2003039466 PCTFULL  ED 20030520  EW 200320
TITLE (ENGLISH):        METHOD OF TREATING OESTROGEN RESPONSIVE BREAST
                        CANCER
TITLE (FRENCH):         METHODE DE TRAITEMENT DU CANCER DU SEIN
```

REPONDANT AUX OESTROGENES

INVENTOR(S): WONG, Grace, 100 Arlington Road, Brookline, MA 02467, US [CN, US];
ESHKOL, Aliza, Ch. Du Petit Molard 1, CH-Ch-1278 La Rippe, CH [IL, CH];
DELUCA, Giampiero, Chemin de la Florence 15, CH-1208 Geneva, CH [IT, CH]

PATENT ASSIGNEE(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V., Pietermaai 15, Curacao, AN [NL, NL], for all designates States except US;
WONG, Grace, 100 Arlington Road, Brookline, MA 02467, US [CN, US], for US only;
ESHKOL, Aliza, Ch. Du Petit Molard 1, CH-Ch-1278 La Rippe, CH [IL, CH], for US only;
DELUCA, Giampiero, Chemin de la Florence 15, CH-1208 Geneva, CH [IT, CH], for US only

AGENT: EISENSTEIN, Ronald, I.$, Nixon Peabody LLP, 101 Federal Street, Boston, MA 02110$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003039466	A2	20030515

DESIGNATED STATES

W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US35438 A 20021105
PRIORITY INFO.: US 2001-60/332,939 20011106

=> d ibib l14 1

L14 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2005058297 PCTFULL ED 20050706 EW 200526
TITLE (ENGLISH): USE OF 4-HYDROXYTAMOXIFEN FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF GYNECOMASTIA
TITLE (FRENCH): UTILISATION DE 4-HYDROXYTAMOXIFENE DANS LA PREPARATION D'UN MEDICAMENT DESTINE AU TRAITEMENT DE LA GYNECOMASTIE

INVENTOR(S): LE NESTOUR, Elisabeth, 6, rue de Chaufourmiers, F-75019 Paris, FR [FR, FR];
PALUMBO, Andrew, R., 7505 Colonial Road, Brooklyn, NY 11209-2905, US [US, US]

PATENT ASSIGNEE(S): LABORATOIRES BESINS INTERNATIONAL, 5, rue du Bourg l'Abbe, F-75003 Paris, FR [FR, FR], for all designates States except US;
LE NESTOUR, Elisabeth, 6, rue de Chaufourmiers, F-75019 Paris, FR [FR, FR], for US only;
PALUMBO, Andrew, R., 7505 Colonial Road, Brooklyn, NY 11209-2905, US [US, US], for US only

AGENT: NARGOLWALLA, Cyra$, Cabinet Plasseraud, 65/67, rue de la Victoire, F-75440 Paris Cedex 09$, FR

```
LANGUAGE OF FILING:     English
LANGUAGE OF PUBL.:      English
DOCUMENT TYPE:          Patent
PATENT INFORMATION:
                        NUMBER              KIND     DATE
                        ---------------------------------
                        WO 2005058297        A1 20050630
DESIGNATED STATES
       W:               AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO
                        CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR
                        HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
                        MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO
                        RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
                        VC VN YU ZA ZM ZW
       RW (ARIPO):      BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
       RW (EAPO):       AM AZ BY KG KZ MD RU TJ TM
       RW (EPO):        AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT
                        LT LU MC NL PL PT RO SE SI SK TR
       RW (OAPI):       BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:      WO 2004-EP14295      A  20041213
PRIORITY INFO.:         EP 2003-03293156.0      20031215
                        US 2003-10/734,640      20031215


=> d his

     (FILE 'HOME' ENTERED AT 08:51:47 ON 11 AUG 2005)

     FILE 'PCTFULL' ENTERED AT 08:52:01 ON 11 AUG 2005
L1          268 S HYDROXYTAMOXIFEN OR (HYRDROXY TAMOXIFEN)
L2         5061 S TAMOXIFEN
L3           67 S L2/AB
L4           25 S L2/TI
L5         5061 S L4 OR L2
L6           70 S L4 OR L3
L7        34444 S BREAST OR MAMMAR?
L8        88096 S CANCER? OR TUMOR? OR NEOPLAS?
L9         2015 S L7/AB
L10        1529 S L9 AND L8
L11       57173 S PERCUTANEOUS? OR TOPICAL?
L12         498 S L11 AND L10
L13          10 S L12 AND L6
L14           5 S L13 AND L1
L15           1 S L14 NOT PY>2002
L16           2 S L14 NOT PY>2003

=> s l2 and l2
L17       5061 L2 AND L2

=> s l17 and l12
L18        145 L17 AND L12

=> s l2/clm
L19        752 (TAMOXIFEN/CLM)

=> s l1/clm
            29 HYDROXYTAMOXIFEN/CLM
             3 HYRDROXY/CLM
           752 TAMOXIFEN/CLM
             0 HYRDROXY TAMOXIFEN/CLM
                 ((HYRDROXY(W)TAMOXIFEN)/CLM)
L20         29 (HYDROXYTAMOXIFEN/CLM OR (HYRDROXY TAMOXIFEN/CLM))
```

```
=> s l20 or l19
L21        757 L20 OR L19

=> s l21 and l18
L22         36 L21 AND L18

=> s l22 not py>2002
        294498 PY>2002
L23         16 L22 NOT PY>2002

=> s l23 not py>2001
        398484 PY>2001
L24         15 L23 NOT PY>2001

=> d ibib 5

L24    ANSWER 5 OF 15    PCTFULL   COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER:       2001054699 PCTFULL  ED 20020827
TITLE (ENGLISH):        SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION
                        WITH ESTROGENS
TITLE (FRENCH):         MODULATEURS SELECTIFS DU RECEPTEUR D'OESTROGENE, EN
                        COMBINAISON AVEC DES OESTROGENES
INVENTOR(S):            LABRIE, Fernand
PATENT ASSIGNEE(S):     ENDORECHERCHE, INC.;
                        LABRIE, Fernand
DOCUMENT TYPE:          Patent
PATENT INFORMATION:
                        NUMBER             KIND     DATE
                        --------------------------------
                        WO 2001054699        A1 20010802
DESIGNATED STATES
       W:               AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
                        CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
                        IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
                        MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
                        TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
                        SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
                        DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
                        CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:      WO 2001-CA86         A  20010126
PRIORITY INFO.:         US 2000-60/178,601      20000128


=> d scan

L24    15 ANSWERS    PCTFULL   COPYRIGHT 2005 Univentio on STN
TIEN   METHOD OF TREATMENT OF PROSTATE CANCER
TIFR   METHODE DE TRAITEMENT DU CANCER DE LA PROSTATE

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L24    15 ANSWERS    PCTFULL   COPYRIGHT 2005 Univentio on STN
TIEN   METHODS FOR IDENTIFYING, TREATING OR MONITORING ASYMPTOMATIC PATIENTS
       FOR RISK REDUCTION OR THERAPEUTIC TREATMENT OF BREAST CANCER
TIFR   PROCEDES D'IDENTIFICATION, DE TRAITEMENT OU DE CONTROLE DES PATIENTS
       ASYMPTOMATIQUES, POUR LA REDUCTION DES RISQUES OU LE TRAITEMENT
       THERAPEUTIQUE DU CANCER DU SEIN

L24    15 ANSWERS    PCTFULL   COPYRIGHT 2005 Univentio on STN
TIEN   BCMP-7 AS MARKER FOR DIAGNOSIS OF BREAST CANCER
TIFR   BCMP 7 EN TANT QUE MARQUEUR POUR LE DIAGNOSTIC DU CANCER DU
```

```
       SEIN

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

     (FILE 'HOME' ENTERED AT 08:51:47 ON 11 AUG 2005)

     FILE 'PCTFULL' ENTERED AT 08:52:01 ON 11 AUG 2005
L1           268 S HYDROXYTAMOXIFEN OR (HYRDROXY TAMOXIFEN)
L2          5061 S TAMOXIFEN
L3            67 S L2/AB
L4            25 S L2/TI
L5          5061 S L4 OR L2
L6            70 S L4 OR L3
L7         34444 S BREAST OR MAMMAR?
L8         88096 S CANCER? OR TUMOR? OR NEOPLAS?
L9          2015 S L7/AB
L10         1529 S L9 AND L8
L11        57173 S PERCUTANEOUS? OR TOPICAL?
L12          498 S L11 AND L10
L13           10 S L12 AND L6
L14            5 S L13 AND L1
L15            1 S L14 NOT PY>2002
L16            2 S L14 NOT PY>2003
L17         5061 S L2 AND L2
L18          145 S L17 AND L12
L19          752 S L2/CLM
L20           29 S L1/CLM
L21          757 S L20 OR L19
L22           36 S L21 AND L18
L23           16 S L22 NOT PY>2002
L24           15 S L23 NOT PY>2001

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 21.54      21.75

STN INTERNATIONAL LOGOFF AT 09:00:36 ON 11 AUG 2005


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1642BJF
```

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02  LMEDLINE coverage updated
 NEWS  3  JUL 02  SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02  CHEMCATS accession numbers revised
 NEWS  5  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16  CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18  CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30  USGENE now available on STN
 NEWS 10  AUG 06  CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06  BEILSTEIN updated with new compounds
 NEWS 12  AUG 06  FSTA enhanced with new thesaurus edition
 NEWS 13  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                  patents
 NEWS 14  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 15  AUG 27  Full-text patent databases enhanced with predefined
                  patent family display formats from INPADOCDB
 NEWS 16  AUG 27  USPATOLD now available on STN
 NEWS 17  AUG 28  CAS REGISTRY enhanced with additional experimental
                  spectral property data
 NEWS 18  SEP 07  STN AnaVist, Version 2.0, now available with Derwent
                  World Patents Index
 NEWS 19  SEP 13  FORIS renamed to SOFIS
 NEWS 20  SEP 13  INPADOCDB enhanced with monthly SDI frequency
 NEWS 21  SEP 17  CA/CAplus enhanced with printed CA page images from
                  1967-1998
 NEWS 22  SEP 17  CAplus coverage extended to include traditional medicine
                  patents
 NEWS 23  SEP 24  EMBASE, EMBAL, and LEMBASE reloaded with enhancements

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:08:20 ON 27 SEP 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:08:40 ON 27 SEP 2007

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2007 HIGHEST RN 948239-70-1
DICTIONARY FILE UPDATES: 26 SEP 2007 HIGHEST RN 948239-70-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s isopropyl myristate
        114659 ISOPROPYL
             2 ISOPROPYLS
        114659 ISOPROPYL
                  (ISOPROPYL OR ISOPROPYLS)
           650 MYRISTATE
             3 MYRISTATES
           650 MYRISTATE
                  (MYRISTATE OR MYRISTATES)
L1           5 ISOPROPYL MYRISTATE
                  (ISOPROPYL(W)MYRISTATE)

=> s isopropyl myristate/cn
L2           1 ISOPROPYL MYRISTATE/CN

=> d cn

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
CN   Tetradecanoic acid, 1-methylethyl ester  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Myristic acid, isopropyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN   1-Methylethyl tetradecanoate
CN   Bisomel
CN   Crodacol IPM
CN   Crodamol IPM
CN   D 50
CN   D 50 (emollient)
CN   Deltyl Extra
CN   Emcol IM
CN   Emerest 2314
CN   Estol 1512
CN   Estol 1514
CN   Estol IPM 1512
CN   IPM
CN   IPM 100
```

CN IPM-EX
CN IPM-R
CN Isomyst
CN Isopropyl myristate
CN Isopropyl tetradecanoate
CN Kessco IPM
CN Kesscomir
CN Lexol IPM
CN Nikkol IPM
CN Nikkol IPM 100
CN NSC 406280
CN Pelemol IPM
CN Promyr
CN Radia 7190
CN Rilanit IPM
CN Sinnoester MIP
CN Stepan D 50
CN Stepan IPM
CN Tegosoft M
CN Wickenol 101

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.15	18.36

FILE 'CAPLUS' ENTERED AT 07:10:21 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Sep 2007 VOL 147 ISS 14
FILE LAST UPDATED: 26 Sep 2007 (20070926/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3 3572 L2

=> s percutaneous (L) l3
9742 PERCUTANEOUS
L4 75 PERCUTANEOUS (L) L3

=> s hydroxypropylcellulose/cn
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

```
L6           0 L5

=> s hydroxypropylcellulose
          2579 HYDROXYPROPYLCELLULOSE
             5 HYDROXYPROPYLCELLULOSES
L7        2581 HYDROXYPROPYLCELLULOSE
                (HYDROXYPROPYLCELLULOSE OR HYDROXYPROPYLCELLULOSES)

=> s l7 and l4
L8           0 L7 AND L4

=> s l4 not py>1999
       8584294 PY>1999
L9          28 L4 NOT PY>1999

=> d ibib 1-5

L9   ANSWER 1 OF 28  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2000:252431  CAPLUS
DOCUMENT NUMBER:         133:63806
TITLE:                   Influence of additives on percutaneous absorption of
                         piroxicam from cataplasm
AUTHOR(S):               Okuyama, Hirohisa; Ikeda, Yasuo; Imamori, Katsumi;
                         Takayama, Kozo; Nagai, Tsuneji
CORPORATE SOURCE:        Central Res. Lab., SSP Co., Ltd., Narita, 286-8511,
                         Japan
SOURCE:                  Drug Delivery System (1999), 14(6), 491-497
                         CODEN: DDSYEI; ISSN: 0913-5006
PUBLISHER:               Nippon DDS Gakkai Jimukyoku
DOCUMENT TYPE:           Journal
LANGUAGE:                Japanese

L9   ANSWER 2 OF 28  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        1998:780838  CAPLUS
DOCUMENT NUMBER:         130:257241
TITLE:                   Influence of propylene glycol and isopropyl myristate
                         on the in vitro percutaneous penetration of diclofenac
                         sodium from carbopol gels
AUTHOR(S):               Arellano, A.; Santoyo, S.; Martin, C.; Ygartua, P.
CORPORATE SOURCE:        Facultad de Farmacia, Departamento de Farmacia y
                         Tecnologia Farmaceutica, Universidad de Navarra,
                         Pamplona, 31080, Spain
SOURCE:                  European Journal of Pharmaceutical Sciences (1999),
                         7(2), 129-135
                         CODEN: EPSCED; ISSN: 0928-0987
PUBLISHER:               Elsevier Science Ireland Ltd.
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         33    THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 3 OF 28  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        1998:459627  CAPLUS
DOCUMENT NUMBER:         129:280861
TITLE:                   Enhancement of percutaneous absorption of ketoprofen:
```

effect of vehicles and adhesive matrix
AUTHOR(S): Cho, Y.-J.; Choi, H.-K.
CORPORATE SOURCE: College of Pharmacy, Chosun University, Kwangju, 501-759, S. Korea
SOURCE: International Journal of Pharmaceutics (1998), 169(1), 95-104
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:430663 CAPLUS
DOCUMENT NUMBER: 129:86064
TITLE: Patches containing melatonin with good percutaneous absorption and manufacture thereof
INVENTOR(S): Hidaka, Yoshifumi; Kato, Toshiyuki
PATENT ASSIGNEE(S): Teisan Seiyaku K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10182455	A	19980707	JP 1996-343279	19961224
PRIORITY APPLN. INFO.:			JP 1996-343279	19961224

L9 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:3676 CAPLUS
DOCUMENT NUMBER: 128:79882
TITLE: Influence of permeation enhancers on the in-vivo percutaneous absorption of indomethacin
AUTHOR(S): Rao, P. Rama; Srinivas, V.; Diwan, Prakash V.
CORPORATE SOURCE: Pharmacology Division, Indian Institute Chemical Technology, Hyderabad, 500 007, India
SOURCE: Eastern Pharmacist (1997), 40(476), 155-158
CODEN: EAPHA6; ISSN: 0012-8872
PUBLISHER: Eastern Pharmacist
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib 6-10

L9 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:790366 CAPLUS
DOCUMENT NUMBER: 128:93107
TITLE: Percutaneous absorption and histopathology of a poloxamer-based formulation of capsaicin analog
AUTHOR(S): Lee, Beom-Jin; Lee, Tae-Sup; Cha, Bong-Jin; Kim, Soon-Hoe; Kim, Won-Bae
CORPORATE SOURCE: College of Pharmacy, Biological Rhythm and Controlled Release Laboratory, Kangwon National University, Chuncheon, 200-701, S. Korea
SOURCE: International Journal of Pharmaceutics (1997), 159(1),

105-114
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:720069 CAPLUS
DOCUMENT NUMBER: 127:351231
TITLE: Alcoholic solutions containing acetylsalicylic acid for percutaneous administration in antithrombotic therapy
INVENTOR(S): Traue, Juergen; Teubner, Andreas; Wadenstorfer, Elmar
PATENT ASSIGNEE(S): Luitpold Pharma Gmbh, Germany
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 803254	A1	19971029	EP 1997-106900	19970425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
DE 19616539	A1	19971106	DE 1996-19616539	19960425
CA 2199920	A1	19971025	CA 1997-2199920	19970313
JP 10045599	A	19980217	JP 1997-118630	19970423
US 5900412	A	19990504	US 1997-845386	19970425
PRIORITY APPLN. INFO.:			DE 1996-19616539 A	19960425

L9 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:641893 CAPLUS
DOCUMENT NUMBER: 127:283277
TITLE: Percutaneous absorption of LHRH through porcine skin: effect of N-methyl 2-pyrrolidone and isopropyl myristate
AUTHOR(S): Bhatia, K. S.; Singh, J.
CORPORATE SOURCE: Dep. Pharmaceutical Sci., Coll. Pharmacy, North Dakota State Univ., Fargo, ND, 58105, USA
SOURCE: Drug Development and Industrial Pharmacy (1997), 23(11), 1111-1114
CODEN: DDIPD8; ISSN: 0363-9045
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:583214 CAPLUS
DOCUMENT NUMBER: 125:308799
TITLE: In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin
AUTHOR(S): Santoyo, S.; Arellano, A.; Ygartua, P.; Martin, C.
CORPORATE SOURCE: Departamento de Farmacia y Tecnologia Farmaceutica, Facultad de Farmacia, Universidad de Navarra, Apt. 273, Pamplona, 31080, Spain
SOURCE: Pharmaceutica Acta Helvetiae (1996), 71(2), 141-146

CODEN: PAHEAA; ISSN: 0031-6865
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

L9 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:986597 CAPLUS
DOCUMENT NUMBER: 124:15517
TITLE: Percutaneous pharmaceutical preparations containing buprenorphine
INVENTOR(S): Tokuda, Shoichi; Ninomiya, Kazuhisa; Fukushima, Yasuhiro; Watanabe, Shigeyuki; Ochai, Mitsuru; Okumura, Mutsuo; Hosokawa, Yuko
PATENT ASSIGNEE(S): Nitto Denko Corp., Japan; Nikken Chemicals Co., Ltd.
SOURCE: Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 680754	A2	19951108	EP 1995-106861	19950505
EP 680754	A3	19960306		
EP 680754	B1	19980930		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07304672	A	19951121	JP 1994-94241	19940506
JP 2819236	B2	19981030		
CA 2147918	A1	19951107	CA 1995-2147918	19950426
AT 171619	T	19981015	AT 1995-106861	19950505
ES 2123177	T3	19990101	ES 1995-106861	19950505
CN 1116525	A	19960214	CN 1995-107104	19950506
PRIORITY APPLN. INFO.:			JP 1994-94241 A	19940506

=> d kwic 7

L9 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
IT 67-63-0, Isopropanol, biological studies 105-99-7, Butyl adipate
110-27-0, Isopropyl myristate 6938-94-9, Isopropyl adipate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alc. solns. containing acetylsalicylic acid for percutaneous administration in antithrombotic therapy)

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 18.51 45.22

FILE 'REGISTRY' ENTERED AT 07:14:11 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2007 HIGHEST RN 948239-70-1
DICTIONARY FILE UPDATES: 26 SEP 2007 HIGHEST RN 948239-70-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> E "HYDROXYPROPYL CELLUSLOSE"/CN 25
E1            1     HYDROXYPROPYL CELLULOSE-METHYL METHACRYLATE GRAFT COPOLYMER/CN
E2            1     HYDROXYPROPYL CELLULOSE-VINYLPHOSPHONIC ACID GRAFT COPOLYMER/CN
E3            0 --> HYDROXYPROPYL CELLUSLOSE/CN
E4            1     HYDROXYPROPYL CHITOSAN/CN
E5            1     HYDROXYPROPYL CHITOSAN ACETATE/CN
E6            1     HYDROXYPROPYL CHITOSAN-METHACRYLIC ACID GRAFT COPOLYMER/CN
E7            1     HYDROXYPROPYL CYANOCELLULOSE/CN
E8            1     HYDROXYPROPYL DEXTRIN/CN
E9            1     HYDROXYPROPYL DEXTRIN SUCCINATE/CN
E10           1     HYDROXYPROPYL DISTARCH PHOSPHATE/CN
E11           1     HYDROXYPROPYL ETHER OF CELLULOSE/CN
E12           1     HYDROXYPROPYL ETHYL CELLULOSE/CN
E13           1     HYDROXYPROPYL ETHYL CELLULOSE PHTHALATE/CN
E14           1     HYDROXYPROPYL ETHYL MALEATE/CN
E15           1     HYDROXYPROPYL ETHYLBENZOIC ACID CELLULOSE ACETATE/CN
E16           1     HYDROXYPROPYL GROUP-CONTG. DI-ME SILOXANES/CN
E17           1     HYDROXYPROPYL GROUP-TERMINATED DI-ME SILOXANES/CN
E18           1     HYDROXYPROPYL GROUP-TERMINATED SILOXANES AND SILICONES/CN
E19           1     HYDROXYPROPYL GUAR/CN
E20           1     HYDROXYPROPYL GUAR GUM/CN
E21           1     HYDROXYPROPYL GUAR GUM ETHER WITH GLYCIDYLTRIMETHYLAMMONIUM
CHLORIDE/CN
E22           1     HYDROXYPROPYL GUAR GUM STEARATE ESTER/CN
E23           1     HYDROXYPROPYL GUAR HYDROXYPROPYLTRIMONIUM CHLORIDE/CN
E24           1     HYDROXYPROPYL GUAR PALMITATE ESTER/CN
E25           1     HYDROXYPROPYL GUAR STEARATE/CN

=> E "HYDROXYPROPYL CELLULOSE"/CN 25
E1            2     HYDROXYPROPYL CARBAMATE/CN
E2            1     HYDROXYPROPYL CARBOXYMETHYL CELLULOSE/CN
E3            1 --> HYDROXYPROPYL CELLULOSE/CN
E4            1     HYDROXYPROPYL CELLULOSE ACETATE/CN
E5            1     HYDROXYPROPYL CELLULOSE ACETATE PHTHALATE/CN
E6            1     HYDROXYPROPYL CELLULOSE ACETATE PHTHALATE SUCCINATE/CN
E7            1     HYDROXYPROPYL CELLULOSE ACETATE SUCCINATE/CN
E8            1     HYDROXYPROPYL CELLULOSE ACETATE SUCCINATE TRIMELLITATE/CN
E9            1     HYDROXYPROPYL CELLULOSE ACETATE TRIMELLITATE/CN
E10           1     HYDROXYPROPYL CELLULOSE ACETATE TRIMELLITATE SUCCINATE/CN
E11           1     HYDROXYPROPYL CELLULOSE ACRYLATE BUTYRATE/CN
E12           1     HYDROXYPROPYL CELLULOSE ACRYLATE BUTYRATE HOMOPOLYMER/CN
E13           1     HYDROXYPROPYL CELLULOSE ACRYLATE BUTYRATE-KAYARAD DPHA
COPOLYMER/CN
E14           1     HYDROXYPROPYL CELLULOSE ACRYLATE BUTYRATE-KAYARAD PEG 400DA
COPOLYMER/CN
E15           1     HYDROXYPROPYL CELLULOSE ACRYLATE BUTYRATE-KAYARAD PET 30I
COPOLYMER/CN
E16           1     HYDROXYPROPYL CELLULOSE ACRYLATE BUTYRATE-KAYARAD RM 1001
COPOLYMER/CN
```

```
E17          1     HYDROXYPROPYL CELLULOSE ACRYLATE PROPIONATE-KAYARAD R 167
COPOLYMER/CN
E18          1     HYDROXYPROPYL CELLULOSE BENZOATE/CN
E19          1     HYDROXYPROPYL CELLULOSE BUTYRATE/CN
E20          1     HYDROXYPROPYL CELLULOSE BUTYRATE HYDROGEN SUCCINATE/CN
E21          1     HYDROXYPROPYL CELLULOSE BUTYRATE PHTHALATE/CN
E22          1     HYDROXYPROPYL CELLULOSE ETHER/CN
E23          1     HYDROXYPROPYL CELLULOSE HYDROGEN PHOSPHONATE/CN
E24          1     HYDROXYPROPYL CELLULOSE ISOBUTYRATE/CN
E25          1     HYDROXYPROPYL CELLULOSE ISOVALERATE/CN

=> S E3
L10          1 "HYDROXYPROPYL CELLULOSE"/CN

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.85      51.07

FILE 'CAPLUS' ENTERED AT 07:15:07 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 27 Sep 2007  VOL 147 ISS 14
FILE LAST UPDATED: 26 Sep 2007  (20070926/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 07:08:20 ON 27 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 07:08:40 ON 27 SEP 2007
L1             5 S ISOPROPYL MYRISTATE
L2             1 S ISOPROPYL MYRISTATE/CN

     FILE 'CAPLUS' ENTERED AT 07:10:21 ON 27 SEP 2007
L3          3572 S L2
L4            75 S PERCUTANEOUS (L) L3
                 S HYDROXYPROPYLCELLULOSE/CN

     FILE 'REGISTRY' ENTERED AT 07:11:15 ON 27 SEP 2007
L5             0 S HYDROXYPROPYLCELLULOSE/CN

     FILE 'CAPLUS' ENTERED AT 07:11:16 ON 27 SEP 2007
L6             0 S L5
L7          2581 S HYDROXYPROPYLCELLULOSE
```

```
L8            0 S L7 AND L4
L9           28 S L4 NOT PY>1999

     FILE 'REGISTRY' ENTERED AT 07:14:11 ON 27 SEP 2007
                E "HYDROXYPROPYL CELLUSLOSE"/CN 25
                E "HYDROXYPROPYL CELLULOSE"/CN 25
L10           1 S E3

     FILE 'CAPLUS' ENTERED AT 07:15:07 ON 27 SEP 2007

=> s l10
L11      11350 L10

=> s l11 and l3
L12        142 L11 AND L3

=> s l11 and l4
L13          1 L11 AND L4

=> d ibib

L13  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2006:888111  CAPLUS
DOCUMENT NUMBER:         145:256238
TITLE:                   Adhesive gels containing acid anhydride copolymers and
                         polyhydric alcohols
INVENTOR(S):             Nihei, Tomoya; Unagami, Runa; Matsuda, Kazuhiko;
                         Yamagata, Yoshifumi; Gotoh, Hajime; Asanuma, Takeyuki;
                         Tagaki, Narumi; Sakamoto, Yasunori
PATENT ASSIGNEE(S):      Lion Corporation, Japan
SOURCE:                  PCT Int. Appl., 34pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                Japanese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2006090824         A1    20060831    WO 2006-JP303391        20060224
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
             NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
             SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
             YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     JP 2006232724         A     20060907    JP 2005-49347           20050224
PRIORITY APPLN. INFO.:                       JP 2005-49347       A   20050224
OTHER SOURCE(S):         MARPAT 145:256238
REFERENCE COUNT:         19    THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 07:08:20 ON 27 SEP 2007)
```

```
     FILE 'REGISTRY' ENTERED AT 07:08:40 ON 27 SEP 2007
L1            5 S ISOPROPYL MYRISTATE
L2            1 S ISOPROPYL MYRISTATE/CN

     FILE 'CAPLUS' ENTERED AT 07:10:21 ON 27 SEP 2007
L3         3572 S L2
L4           75 S PERCUTANEOUS (L) L3
               S HYDROXYPROPYLCELLULOSE/CN

     FILE 'REGISTRY' ENTERED AT 07:11:15 ON 27 SEP 2007
L5            0 S HYDROXYPROPYLCELLULOSE/CN

     FILE 'CAPLUS' ENTERED AT 07:11:16 ON 27 SEP 2007
L6            0 S L5
L7         2581 S HYDROXYPROPYLCELLULOSE
L8            0 S L7 AND L4
L9           28 S L4 NOT PY>1999

     FILE 'REGISTRY' ENTERED AT 07:14:11 ON 27 SEP 2007
               E "HYDROXYPROPYL CELLUSLOSE"/CN 25
               E "HYDROXYPROPYL CELLULOSE"/CN 25
L10           1 S E3

     FILE 'CAPLUS' ENTERED AT 07:15:07 ON 27 SEP 2007
L11       11350 S L10
L12         142 S L11 AND L3
L13           1 S L11 AND L4

=> s percutaneous
L14        9742 PERCUTANEOUS

=> s l14 and l12
L15          10 L14 AND L12

=> s l15 not py>1999
       8584294 PY>1999
L16           1 L15 NOT PY>1999

=> d ibib

L16  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1985:583579  CAPLUS
DOCUMENT NUMBER:          103:183579
TITLE:                    Pharmaceutical for percutaneous application
                          of metoclopramide
INVENTOR(S):              Saito, Kenichiro; Heller, Jorge; Skinner, Wilfred A.
PATENT ASSIGNEE(S):       Nitto Electric Industrial Co., Ltd. , Japan
SOURCE:                   Ger. Offen., 28 pp.
                          CODEN: GWXXBX
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     DE 3503279            A1    19850808    DE 1985-3503279         19850131
     DE 3503279            C2    19890309
     US 4605670            A     19860812    US 1984-576087          19840201
     JP 60161918           A     19850823    JP 1984-175206          19840824
     SE 8405929            A     19850802    SE 1984-5929            19841123
```

```
     SE 465452            B     19910916
     SE 465452            C     19920123
     NL 8403618           A     19850902    NL 1984-3618           19841128
     CA 1252049           A1    19890404    CA 1984-468965         19841129
     GB 2153223           A     19850821    GB 1984-30458          19841203
     GB 2153223           B     19870624
     DK 8500433           A     19850802    DK 1985-433            19850131
     CH 667810            A5    19881115    CH 1985-439            19850131
     FR 2558729           A1    19850802    FR 1985-1459           19850201
     FR 2558729           B1    19881028
PRIORITY APPLN. INFO.:                       US 1984-576087      A  19840201
OTHER SOURCE(S):         MARPAT 103:183579


=> d kwic

L16  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Pharmaceutical for percutaneous application of metoclopramide
AB   Metoclopramide (I)  [364-62-5], for percutaneous administration,
     is incorporated into a carrier system containing monovalent aliphatic C6-24
alcs.
     and/or esters of monovalent alcs. with C8-32 monocarboxylic.  .  .
IT   57-55-6, biological studies   513-85-9   9004-62-0 9004-64-2
     RL: BIOL (Biological study)
        (metoclopramide absorption by skin from pharmaceuticals containing alcs. or
        esters and lactams and)
IT   78-70-6   106-32-1 110-27-0   111-87-5, biological studies
     112-53-8   143-28-2   150-86-7   515-69-5   589-62-8   3234-85-3
     3687-46-5   5333-42-6   58670-89-6
     RL: BIOL (Biological study)
        (metoclopramide absorption by skin from pharmaceuticals containing lactams
        and)


=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       9.78      60.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.78      -0.78

STN INTERNATIONAL LOGOFF AT 07:17:10 ON 27 SEP 2007
```